Business Wire

Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories

Share

Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the Supply Chain and Pharma 4.0™ categories for the 2022 Facility of the Year Awards (FOYA). In the Supply Chain category, Takeda was awarded for its implementation of a new patient-focused supply chain for its allogeneic mesenchymal stem cell therapy; and Takeda’s vaccine production facility in Singen, Germany, won in the Pharma 4.0 category.

“Our approach to manufacturing is driven by our unwavering commitment to address patient needs. These awards further reinforce this mission and showcase the innovation taking place at our state-of-the-art facilities to develop and deliver breakthrough treatments,” says Thomas Wozniewski, global manufacturing and supply officer at Takeda. “We’re proud to be recognized by ISPE in two FOYA categories and look forward to continuing our digital transformation.”

The Supply Chain FOYA recognizes the novel application of principles, systems and management tools aimed at improving operational speed, robustness and response. This award acknowledges Takeda’s work to completely rethink the supply chain management program for Takeda’s first allogeneic mesenchymal stem cell therapy, of which the time for final product to patient administration is just 72 hours. Due to the short shelf-life of allogeneic mesenchymal stem cell therapy and the need for seamless cold chain transportation, speed is essential. Takeda introduced a cloud-based control tower platform to connect its ecosystem (hospitals, transportation companies, plants, business units) for a “make to order” process. The platform enables hospitals to book a manufacturing slot directly via a web portal, then track the final product delivery status through end-to-end visibility and alerts at each step of the supply chain.

In the Pharma 4.0 category, ISPE recognizes facilities which showcase how innovation in advanced digital technologies leads to improved outcomes in terms of safety, product quality and productivity in a pharmaceutical manufacturing facility. Takeda’s vaccine facility in Singen, Germany was built with state-of-the-art process equipment and layered with advanced digital technologies in key areas. In addition, Takeda has a sponsored research collaboration with the School of Engineering at Massachusetts Institute of Technology (MIT) to develop the application to increase inspection accuracy and reduce low false reject rates during routine operations.

About the ISPE Facility of the Year Awards Program

Established in 2004, the Facility of the Year Awards (FOYA) recognizes state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery. The FOYA program provides a platform for the pharmaceutical science and manufacturing industry to showcase its accomplishments in facility design, construction, and operations, while sharing the development of new applications of technology and cutting-edge approaches. For more information, visit https://ispe.org/facility-year-awards.

About Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Japanese Media
Jun Saito
jun.saito@takeda.com

U.S. and International Media
Megan Ostrower
megan.ostrower@takeda.com
+1 772-559-4924

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Booba and Silent Seeds Announce the Launch of a New Strain of Cannabis (THC), the B-45!19.5.2022 11:35:00 CEST | Press release

Alexandre Lacarré, the co-founder of the Silent Seeds seed bank (formerly Dinafem) and the famous French rapper Booba, have announced a unique cooperation to create B-45, a seed specially designed for the artist. A first in Europe! This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005106/en/ (Photo: Silent Seeds) With 20 years of experience and R&D, Silent Seeds was Booba's partner of choice for the creation and distribution of his own strain of cannabis, entirely tailor-made for an exceptional result. Friday 20 May 2022 will mark the launch of B-45, an Indica-dominant hybrid resulting from crossing (Florida OG x Pre'98 Bubba Kush) x Orange Punch #66. This strain has a record THC content of more than 30%. "If you want to visit Jamaica, you just have to taste my weed". -Booba "From our first meeting, Booba knew exactly what he wanted. We soon came to the conclusion that the cannabis plant held no secrets for him. We would

AGIC Capital Acquires a Majority Stake in Grafotronic19.5.2022 11:23:00 CEST | Press release

AGIC Capital, the European-Asian private equity fund focused on investments in high quality industrial and medical companies today announced the acquisition of a majority stake in Grafotronic AB and its subsidiaries (“Grafotronic”), a leading manufacturer of roll-to-roll automated manufacturing solutions, from its current shareholders, for an undisclosed amount. Established in 2004, Grafotronic develops highly distinctive modular solutions for the digital label finishing and EV battery markets. It has achieved substantial growth over the last five years since focusing on the digital finishing segment, and is building its position into manufacturing technologies for a range of products in the EV battery market in partnerships with major players in the field. AGIC was attracted to Grafotronic’s positioning in resilient and high-growth markets, modular product concept, strong innovation capabilities including automation and product / services connectivity, asset-light business model, dedi

FEELM Commits to Net-zero Carbon Emissions By 205019.5.2022 10:41:00 CEST | Press release

FEELM, the flagship atomization tech brand belonging to SMOORE, today released its “Race to Zero” plan and roadmap to carbon neutrality. The plan brings forward FEELM’s ambitions to achieve net-zero carbon emissions by 2050 in its direct production activities and indirect purchased energy (scope 1&2). Meanwhile, FEELM makes a commitment that renewable energies will account for 30% of its total energy consumption by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005482/en/ (Photo: Business Wire) As one of China’s first atomization tech brands to make a carbon neutrality commitment, FEELM pledges to reach net zero in full supply chain and full product lifespan by developing sustainable products, improving energy efficiency with automated production, supporting the supply chain in decarbonization, and increasing renewable energies and eco-friendly materials. FEELM, being the world ‘s largest closed vape system solut

flatexDEGIRO Offers Crypto Trading via Partnership With BISON (Boerse Stuttgart Group)19.5.2022 09:39:00 CEST | Press release

flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR), Europe's largest and fastest growing retail online broker and Boerse Stuttgart Group, Europe's sixth largest exchange group, today announced the signing of a Memorandum of Understanding (MoU) on a partnership in crypto trading. This will give flatexDEGIRO customers direct access to trading in major cryptocurrencies via convenient and direct in-app access from flatex and DEGIRO with an accelerated onboarding process. For this purpose, Boerse Stuttgart Group provides its integrated offer in the crypto business, with uncomplicated trading via the retail platform BISON and use the secure crypto custody service operated by the custodian blocknox. The aim is to launch first at flatex Germany and Austria by the end of the third quarter of 2022, followed by the expansion of the offer to all DEGIRO customers. Frank Niehage, CEO of flatexDEGIRO: "As the European market leader in online stock trading, cryptocurrencies add a key el

Swiss Private Bank Selects Temenos to Digitally Transform Wealth Management Services19.5.2022 09:03:00 CEST | Press release

Temenos (SIX: TEMN), the cloud banking platform, today announced that Mirabaud, the Swiss private bank, has selected Temenos to move from a traditional on-premise system to a digital end-to-end wealth management platform on Temenos Banking Cloud. With the generational transfer of wealth, new regulations and growth in asset classes such as private equity and digital assets, Temenos Banking Cloud gives Mirabaud the agility to quickly adapt to changing investment opportunities and client expectations. Mirabaud will adopt the complete suite of Temenos wealth banking capabilities, from self-service channels and portfolio management to back-office processing, including Payments, Financial Crime Mitigation and Data Lake. The breadth and depth of Temenos wealth capabilities will enable Mirabaud to deliver a digital customer experience with personalized services and highly automated processes. Privacy is and will always remain an absolute key consideration for Mirabaud in selecting its business